Fibrocell Science (FCSC) Stock Price & Overview
NASDAQ:FCSC
Current stock price
The current stock price of FCSC is 3 null. Today FCSC is down by 0%. In the past month the price increased by 0.67%. In the past year, price increased by 50%.
FCSC Key Statistics
- Market Cap
- 29.274M
- P/E
- 16.67
- Fwd P/E
- N/A
- EPS (TTM)
- 0.18
- Dividend Yield
- N/A
FCSC Stock Performance
FCSC Stock Chart
FCSC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to FCSC. When comparing the yearly performance of all stocks, FCSC is one of the better performing stocks in the market, outperforming 82.79% of all stocks.
FCSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FCSC. There are concerns on the financial health of FCSC while its profitability can be described as average.
FCSC Earnings
FCSC Forecast & Estimates
FCSC Financial Highlights
Over the last trailing twelve months FCSC reported a non-GAAP Earnings per Share(EPS) of 0.18000000000000005. The EPS increased by 103.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -3.29% | ||
| ROA | -2.7% | ||
| ROE | N/A | ||
| Debt/Equity | 0.47 |
FCSC Ownership
About FCSC
Company Profile
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.
Company Info
Fibrocell Science
405 EAGLEVIEW BOULEVARD
EXTON PA 19341
CEO: John M. Maslowski
Phone: 484-713-6000
Fibrocell Science / FCSC FAQ
What does FCSC do?
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.
Can you provide the latest stock price for Fibrocell Science?
The current stock price of FCSC is 3 null.
Does Fibrocell Science pay dividends?
FCSC does not pay a dividend.
How is the ChartMill rating for Fibrocell Science?
FCSC has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for Fibrocell Science?
Fibrocell Science (FCSC) has a market capitalization of 29.27M null. This makes FCSC a Nano Cap stock.